In this study in conscious rats, we tested the hypothesis that substance P, a central pressor peptide and a potential transmitter substance of pain pathways, could be involved in the cardiovascular defense reaction that is typically associated with unpleasant sensory stimuli. The hemodynamic responses to centrally administered substance P were pharmacologically characterized. The increases in blood pressure and heart rate after intracerebroventricular injections of substance P were accompanied by mesenteric and renal vasoconstriction and hind limb vasodilation E vidence has accumulated that substance P, a neuropeptide with a wide distribution in the central and peripheral nervous systems, can be considered a neurotransmitter that is involved primarily in the processing of afferent sensory signals, including pain (for review, see References 1-3).
noxious stimuli such as intermittent foot shock and skin heating. 45 Autoradiographically localized binding sites for substance P have been shown to closely correspond to functional substance P receptors as evidenced by the hydrolysis of inositol lipids. The highest density of substance P receptors has been found in the hypothalamus. 6 The presence of substance P and its receptors in brain areas involved in the expression of a variety of behaviors as well as in cardiovascular control has prompted many pharmacological studies to elucidate the function of this peptide in behavioral responses or central blood pressure regulation.
In rats, infusions of substance P into the ventral tegmental area and into the substantia nigra have yielded stereotyped behavioral reactions characterized by increased locomotion and grooming. 78 In mice, intracerebroventricular injections of the peptide induced a unique hind limb scratching response that was dose-dependent and could be prevented by analgesic narcotic agents. 9 With respect to its central cardiovascular effects, substance P injected intracerebroventricularly and into hypothalamic nuclei of conscious rats elicits dose-dependent pressor responses as well as sympathoadrenal activation. 10 - 12 The cardiovascular responses were invariably associated with a behavioral arousal reaction, including increased locomotion, scratching, skin biting, and grooming.
To date, no attempt has been made to conceptually link the central behavioral with the central cardiovascular actions of substance P. Therefore, in the present study, we have investigated whether the cardiovascular response to central substance P is part of a more general response pattern, such as the defense reaction, or the closely related nociceptive reaction, 1314 where cardiovascular adjustments enable the individual to express an adequate behavioral response to the respective stimulus.
Such reflex responses can be distinguished on the basis of regional blood flow distribution. 1313 Therefore, the study was particularly designed to characterize the substance P-induced changes in local vascular resistance and to analyse the hormonal and neuronal effector mechanisms involved.
Our findings demonstrate that stimulation of periventricular substance P receptors elicits an integrated response showing the hemodynamic features of the classic defense reaction. These findings are compatible with the idea that substance P may not only transmit pain signals to the brain but may also be involved in the integration of the efferent output in response to sensory stimuli.
Materials and Methods

Experimental Animals and Procedures
Experiments were performed in conscious male Wistar rats weighing between 300 and 350 g (Thomae, Biberach, FRG). Animals were kept under controlled conditions with respect to temperature, humidity, and periods of light. For intracerebro ventricular injections, chronic cannulae (PP20, Portex, UK) were implanted into the lateral brain ventricle 1-2 weeks before the experiments, and carotid artery and femoral vein catheters were implanted 2-7 days before the acute experiments. The surgical procedures have been described previously. 10 Measurements of mean arterial blood pressure (MAP) and heart rate (HR) were performed via the arterial line with a Statham P23Db pressure transducer (Cleveland, Ohio) and a Gould Brush pressure computer (Cleveland, Ohio) coupled to a Gould Brush 2400 recorder.
Regional blood flow measurements were performed with an ultrasonic pulsed-Doppler flowmeter (Bioengineering Department, University of Iowa, Iowa City, Iowa). Probes with different diameters (18, 20 , and 22 gauge) were used for measuring blood flow in the lower aorta (hind limb [HLF]), mesenteric (MBF), and renal arteries (RBF). Chronic implantation of flow probes was performed as described by Haywood et al 16 with the exception that we used different miniconnectors, which were exited at the nape of the neck. A recovery period of 1 week was allowed after implantation of the flow probes until the arterial and venous catheters were inserted. Blood flow was measured as Doppler flow velocity (kHz shift) and recorded continuously on a Gould Brush 2400 recorder. Peripheral vascular resistance was calculated according to the relation of Ohm (mean arterial blood pressure divided by blood flow) and is given in millimeters mercury per kilohertz. In most experiments, MBF was measured together with either RBF or HLF. In one experiment (experiment 3), substance P-induced changes in MBF and HLF were recorded in separate groups. Recordings were done while the animals were resting comfortably in their home cages. Baseline values before injections were obtained 60 minutes after the animals were connected to the different recording devices.
In three animals, efferent splanchnic nerve activity was recorded in addition to the above hemodynamic parameters by means of chronically implanted bipolar electrodes. This enabled us to directly correlate changes in blood flow to corresponding changes in sympathetic nerve activity. The surgical and technical procedures for measuring sympathetic nerve activity in conscious rats have been described previously. 17 The experimental protocols were approved by the German governmental ethics committee on animal experimentation. In three additional animals, efferent splanchnic nerve activity (SpNA) was recorded with MAP, HR, and MBF.
Experiment 2: Effect of peripheral pretreatment with a vascular (V,)-vasopressin receptor antagonist on the hemodynamic responses to intracerebroventricular substance P. This experiment was performed 1 day after experiment 1 in the same animals with the same protocol with the exception that 5 minutes before the substance P injection, the rats were pretreated with 10 /xg/kg d(CH2) 5 Tyr(Me) arginine vasopressin (AVP) i.v., a vascular (V,)-vasopressin receptor antagonist. 18 The dose of the antagonist was sufficient to abolish the hemodynamic responses to intravenous injections of 10 ng AVP for about 2 hours. Experiment 5: Pharmacological characterization of the hind limb vasodilation induced by substance P. ft-ADRENOCEPTOR BLOCKADE. This experiment was performed to detect a possible /3-adrenergic component of the hind limb vasodilation to intracerebroventricular substance P. Rats (/i = 8) were divided into two groups (n = 4 each) and subjected to a crossover experiment on two consecutive days.
On day 1, group 5a was pretreated with the selective /3 2 -adrenoceptor antagonist ICI 118,551 (1 mg/kg i.v.). The dose used prevented the hind limb vasodilation in response to injections of the f%-adrenoceptor agonist salbutamol (1 fig/kg i.v.) during the time of the experiment. Five minutes after the intravenous injection of the antagonist, substance P (1 fig) was injected intracerebroventricularly. On day 2, vehicle (0.9% NaCl) instead of the ft-antagonist was given intravenously, and substance P injections were repeated. Group 5b underwent the same protocol in reverse order. MAP, HR, and HLF were recorded.
MUSCARINIC RECEPTOR BLOCKADE. In this experiment, we investigated whether the substance Pinduced hind limb vasodilation was mediated by a sympathetic cholinergjc pathway.
Rats {n = 6) were divided into two equal groups and subjected to a crossover experiment. On day 1, group 5c was pretreated with atropine (1 mg/kg i.v.). The dosage used prevented the depressor responses to injections of the muscarinic receptor agonist acetylmethylcholine (3 /ng/kg i.v.) during the experiment. Five minutes after the atropine injection, substance P (1 fig i. c.v.) was injected. On day 2, rats received vehicle (0.9% NaCl) instead of atropine before the substance P injections. Group 5d underwent the same protocol in reverse order with respect to days 1 and 2. MAP, HR, and HLF were recorded.
Experiment 6: Effect of intracerebroventricular substance P on hormone release from the pituitary gland. Animals were handled daily during the week before the experiment to minimize environmental and procedural influences on plasma hormone levels.
VASOPRESSIN AND OXYTOCIN. Rats were divided in four groups and were injected intracerebroventricularly with 0.9% NaCl (vehicle control, /i = 8), 0.01
, or 10 jig substance P (/i = 7). Injection volumes were 5 fi\. Ninety seconds later, the animals were decapitated, and blood from the trunk (5 ml) was collected into heparinized tubes. Plasma AVP and oxytocin were determined by radioimmunoassay as described previously. 19 -20 ADRENOCORTICOTROPIC HORMONE. Rats were divided into four groups (« = 10 each) and were injected intracerebroventricularly with 1 fig substance P, 10 fig substance P, 100 ng angiotensin 11 (Ang II), or 0.9% NaCl. Ninety seconds later, the animals were decapitated, and plasma adrenocorticotropic hormone (ACTH) was measured by radioimmunoassay as described elsewhere. 21 Angiotensin II was used in this experiment as a stimulatory control, whereas sodium chloride served as a vehicle control. 
Drugs
Substance P and Ang II were purchased from Bachem, Bubendorf, Switzerland. AVP was purchased from Serva, Heidelberg, FRG. The AVP-V, receptor antagonist d(CH2) 5 Tyr(Me) AVP was a gift from Dr. M. Manning, Toledo, Ohio. Isoprenaline was from Boehringer Ingelheim, FRG. Prazosin was supplied by Pfizer, Karlsruhe, FRG. The &-adrenoceptor antagonist ICI118,551 was a gift from ICI, Macclesfield, UK. Metoprolol tartrate, atropine sulfate, acetylmethylcholine chloride, and salbutamol sulfate were purchased from Sigma Chemical, Munchen, FRG. The pharmacologically efficient blocking doses were tested in separate experiments.
Peptides and other agents were dissolved in sterile 0.9% NaCl. Stock solutions were stored at -20° C and diluted with 0.9% NaCl before use. Prazosin was dissolved in a solution containing 5% glycerol and 5% glucose before use.
Statistics
Results are reported as mean±SEM. For statistical evaluation, a two-way analysis of variance (ANOVA), repeated measures ANOVA, or Student's t test for paired and unpaired observations were used as appropriate with a computerized statistical package (SPSS-X). A significance level of p<0.05 was accepted.
Results
Experiment I: Effect of intracerebroventricular substance P on blood pressure, heart rate, and regional blood flow (Table 1, Figures 1-2) . The injection of 1 ^tg substance P i.c.v. increased MAP with a latency of about 60 seconds and a peak after about 5 minutes. Baseline values were restored after 10-20 minutes. The pressor responses were accompanied by a marked increase in HR, a drastic decrease in MBF, a moderate decrease in RBF, and a marked increase in HLF. In most cases, the onset of the changes in HR and regional blood flow preceded the onset of the blood pressure increases. 
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Behaviorally, the blood pressure increases were accompanied by an arousal reaction characterized by increased locomotion with intermittent periods of grooming, scratching, and skin biting. The onset of the increase in HR and HLF consistently preceded the onset of the behavioral responses.
Experiment 2: Effect of peripheral pretreatment with a vascular vasopressin antagonist on the hemodynamic responses to intracerebroventricular substance P (Figure 3 ). Intravenous pretreatment with the V r AVP receptor antagonist did not change the hemodynamic baseline variables. The pressor and tachycardic responses to substance P were not significantly influenced by pretreatment with the V,-AVP receptor antagonist ( + 25 ±3 mm Hg vs. a control response of +27 ±3 mm Hg and +126 ±7 vs. + 131 ± 8 beats/min). Also, the V,-AVP receptor antagonist did not change the responses in local vascular resistance to intracerebroventricular substance P (Figure 3) . (Figure 4) . The intravenous infusion of prazosin caused an increase in heart rate from 398 ±27 to 499 ±16 beats/min (p<0.05) and a fall in blood pressure (Figure 4 ). Under peripheral a r adrenoceptor blockade, substance P caused an initial decrease in blood pressure (-18.6±1.8 mm Hg, p<0.001), which was followed about 2 minutes later by a moderate rise in blood pressure with a peak (+12.2 ±1.5 mm Hg, p<0.01) about 5 minutes after peptide injection. The maximal fall in MR associated with the substance P-induced pressor response was inhibited to a similar degree ( -66%) as was the increase in blood pressure (-50%) (Figure 4 ). Intravenous 
Experiment 3: Effect of peripheral a,-adrenoceptor blockade on the hemodynamic responses to intracerebroventricular substance P
FIGURE 3. Plots of maximal responses in local vascular resistance after intracerebroventricular injections of substance P before and after intravenous pretreatment with the V,-vasopressin (AVP) receptor antagonist d(CH 2 ) 5 Tyr(Me) AVP. Before the antagonist, all substance P-induced changes in vascular resistance were statistically significant (p<0.05-0.001). Pretreatment with the AVP antagonist did not affect the substance Pinduced changes in mesenteric, renal, or hind limb vascular resistance.
prazosin did not affect the substance P-induced hind limb vasodilatation associated with the pressor response (Figure 4 ), although the initial depressor response was accompanied by a marked fall in hind limb resistance (from 18.6 ±2.9 to 11.2 ±1.7 mm Hg/kHz, p<0.01). (Figure 5 ). Intravenous pretreatment with the /3,-adrenoceptor antagonist metoprolol reduced the pressor responses to intracerebroventricular substance P by 30% when compared with the vehicle-pretreated control group and prevented the tachycardic actions of the peptide. The baseline values for MAP and HR were not changed by metoprolol (MAP, 112±4 vs. lll±4mm Hg; HR, 320 ± 14 vs. 308 ± 12 beats/min). (Figure 6 ). ft-ADRENOCEPTOR BLOCKADE. Intravenous administration of the ftadrenoceptor antagonist ICI 118,551 did not significantly alter baseline hemodynamics measured. The pressor and tachycardic responses to intracerebroventricular substance P were not changed significantly after pretreatment with the ft-adrenoceptor antagonist ( + 26 ±3 vs. +23 ±3 mm Hg in controls and +79±17vs. + 102 ± 16 beats/min in controls). However, the substance P-induced increase in hind limb flow was reduced to an initial short peak of less than 30 seconds' duration, the sustained phase of the response being virtually abolished ( Figure 6) . Consequently, the decrease in HLR seen in con- trols at the time of the peak pressor response was reversed to a marked increase in the pretreated animals (from -1.2±0.5 in controls to +5.8±2.4 mm Hg/kHz). MUSCARINIC RECEPTOR BLOCKADE. The intravenous administration of atropine significantly increased resting heart rate ( + 78 ±13 beats/min, p<0.01). Under atropine pretreatment, the tachycardic responses to substance P were reduced by 54% (p<0.05) but the pressor responses (+18±3 vs. +21 ±2 mm Hg) and the hind limb vasodilation ( Figure 6) were not altered significantly.
Experiment 4: Effect of peripheral $ r adrenoceptor blockade on the pressor and tachycardic actions of intracerebroventricular substance P
Experiment 5: Pharmacological characterization of hind limb vasodilation induced by intracerebroventricular substance P
Experiment 6: Effect of intracerebroventricular substance P on hormone release from the pituitary gland (Figures 7 and 8) . After intracerebroventricular injections of substance P, plasma levels of oxytocin increased dose-dependently, the maximal effect being reached after a dose of 0.1 /xg, while plasma AVP remained unaltered (Figure 7) . Plasma ACTH was unchanged after injections of 1 /xg substance P i.c.v. when compared with sodium chloride control injections and after 10 fig substance P, plasma ACTH was reduced. In contrast, injections of 100 ng Ang II i.c.v. produced a more than fourfold increase in plasma ACTH (Figure 8 ).
Discussion
Stimulation of substance P receptors in periventricular brain structures induced a distinct hemodynamic response, characterized by a rise in heart rate and blood pressure associated with hind limb vasodilation and visceral vasoconstriction. Together with the previously demonstrated increases in cardiac output and efferent splanchnic, renal, and adrenal nerve activity, 12 this response fulfills the cardiovascular criteria of a classic defense reaction.
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The behavioral component of the substance Pinduced response is more difficult to interpret because in the rat the behavioral expression of the defense reaction has not yet been clearly characterized. However, at least parts of the substance P-induced behavioral reactions, such as arousal, scratching, and skin biting, are consistent with behavioral responses to nociceptive stimuli in rodents.
-24
The central cardiovascular actions of substance P are brought about by a sympathoadrenal stimulation. This was evidenced previously by the demonstration of marked increases in efferent sympathetic nerve activity, plasma noradrenaline and adrenaline concentrations, cardiac output, and heart rate 12 and in the present study by the inhibitory effects of peripheral a r and /3,-adrenoceptor blockade on the substance P-induced hemodynamic changes.
Prazosin pretreatment reversed the initial portion of the substance P-induced pressor to a depressor response, associated with a marked fall in hind limb resistance. The most likely explanation for this finding is that the a-blocker induced a classic "adrenaline reversal" reaction where the ^-induced vasodilation is not opposed by an enhanced a r vasoconstrictor tonus. The subsequent blood pressure increase despite continuous prazosin infusion, can be partly explained by an increase in cardiac output 12 and partly by the fact that prazosin did not completely abolish the substance P-induced vasoconstriction. It appears, therefore, that this vasoconstriction has an additional component unrelated to vascular a,-adrenoceptor stimulation.
Substance P caused a pronounced and sustained dilation of the hind limb vasculature. According to Hilton, 13 skeletal muscle vasodilation represents the best objective index of defense-type reactions. Neurophysiological studies have revealed that, depending on species and site of electrical stimulation, this vasodilation can be brought about by different effector mechanisms. In cats and dogs, In the cat brain, Coote et al 27 have localized an additional area stretching from the inferior colliculus to the floor of the fourth ventricle from which they elicited a typical defense reaction by electrical stimulation. The hind limb vasodilation was not sensitive to atropine but was greatly reduced by guanethidine. Subsequently, Horeysek et al 28 demonstrated a specific active withdrawal of sympathetic vasoconstrictor tone in the skeletal muscle after electrical stimulation of the hypothalamic defense area.
Finally, in conscious baboons, a delayed vasodilation of the skeletal muscle was observed within a defenselike reaction, which was sensitive to /Jadrenoceptor blockade, suggesting an involvement of circulating adrenaline. 29 In view of these previous findings, we sought to characterize possible cholinergic and adrenergic mechanisms involved in the hind limb vasodilation to substance P. In agreement with studies in rats by Bolme et al, 26 we were unable to demonstrate a cholinergic component as evidenced by the failure of atropine to influence the vasodilator response. Neither was the hind limb vasodilation sensitive to a,-adrenoceptor blockade, which excludes the possibility that an active withdrawal of the sympathetic vasoconstrictor tone contributes to the response.
On the other hand, the substance P-induced increase in hind limb flow was-with the exception of a short initial flow peak-prevented by pretreatment with a selective ft-adrenoceptor antagonist, indicating that the hind limb vasodilation is predominantly mediated through stimulation of vascular -adrenoceptors. We have previously demonstrated that the response to central substance P includes a stimulation of the efferent adrenal nerve and a release of adrenaline into the circulation. 12 Therefore, in accordance with the results by Smith et al, 29 circulating adrenaline may be responsible for the /^-adrenoceptor-mediated component of the hind limb vasodilation to substance P.
The initial short component of the substance Pinduced hind limb vasodilation is obviously independent of vascular adrenoceptors and most likely attributed to an acute redistribution of blood flow from areas of vasoconstriction to the skeletal muscle.
Another important differentiation between the immediate versus the delayed hind limb vasodilation concerns their respective relation to muscular exercise and blood pressure increase. As shown on a representative recording (Figure IB) , the immediate hind limb vasodilation after central substance P administration usually preceded the blood pressure increase. Furthermore, hind limb vasodilation, visceral vasoconstriction, and tachycardia consistently preceded the behavioral response. Therefore, the initial regional hemodynamic changes were not secondary to increased blood pressure or to muscular exercise but clearly anticipatory in character. During the delayed phase, muscular exercise such as grooming and blood pressure increases may have contributed to increased blood flow in the hind limb. However, this possibility appears unlikely for two reasons. First, similar blood pressure increases and increased locomotion after central Ang II injections did not produce hind limb vasodilation (T. Unger et al, manuscript in preparation) and, second, grooming was shown to be associated with reduced and not increased blood flow in the inactive hind limbs. 30 Defenselike reactions have traditionally been linked to a distinct pattern of hormonal changes, including the release of ACTH and AVP from the pituitary, in addition to increased circulating catecholamines. 14 However, more recently, we found in rats that various forms of stress, such as physical immobilization and forced swimming, caused substantial increases in the secretion of oxytocin but not of AVP. 20 Similarly, in the present study, the hemodynamic and behavioral responses to substance P were accompanied by release of oxytocin but not of AVP from the pituitary gland. In addition, circulating ACTH remained either unchanged or was even decreased after higher intracerebroventricular doses of substance P, whereas Ang II, without producing any signs of a defenselike reaction, 12 markedly stimulated the secretion of this hormone. These findings demonstrate that the hemodynamic pattern of a defense reaction can be clearly dissociated from increased AVP or ACTH secretion. The function of oxytocin in stress reactions remains to be elucidated.
Recently, Shekhar and Di Micco 31 reported on a defenselike reaction after the injection of GABA antagonists or GABA synthesis inhibitors into the posterior hypothalamus of conscious rats. In view of the fact that hypothalamic are?s were identified as sensitive to the cardiovascular actions of substance P," it is tempting to speculate that the substance P-induced defense reaction originates from the hypothalamus and is-at least in partunder tonic inhibitory control by the GABA-ergic system. In addition, according to Hilton and Redfern, 32 other nonhypothalamic brain areas, such as the periaqueductal gray matter, may also be involved in the generation of defenselike reactions in rats, although these areas have not yet been demonstrated to be substance P-sensitive.
In summary, we have presented evidence that substance P injected into the lateral brain ventricle of conscious rats elicits a behavioral arousal reac-tion together with a cardiovascular response with the features of a classic defense reaction.
The substance P-induced blood pressure increases are mainly attributable to a r adrenoceptor-mediated vasoconstriction and, to a minor extent, to increased cardiac output through stimulation of cardiac /3 r adrenoceptors. The hind limb vasodilation does not involve a cholinergic pathway or an active withdrawal of sympathetic aradrenoceptor-mediated vascular tone but appears to be initiated by redistribution of blood flow to the skeletal muscle, and it is subsequently maintained by stimulation of vascular ft-adrenoceptors. The newly described endocrine component of the substance P response features an increased secretion of the stress-related hormone oxytocin but not of AVP and ACTH.
In view of the close relation between defense responses and nociceptive responses, we propose that substance P, in addition to its presumptive function as a neurotransmitter in sensory afferents, is involved-possibly at the hypothalamic level-in the generation of basic efferent response patterns to sensory stimuli, including those of pain.
